Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up

Charlotte Charpentier, Minh Patrick Lê, Véronique Joly, Benoit Visseaux, Sylvie Lariven, Bao Phung, Patrick Yéni, Yazdan Yazdanpanah, Diane Descamps, Gilles Peytavin and Roland Landman

PLOS ONE, 2015, vol. 10, issue 7, 1-10

Abstract: Objective: To assess, in a clinical cohort, the efficacy of switching treatment in virologically-suppressed patients to tenofovir/emtricitabine/rilpivirine as a single-tablet regimen (STR) using the PCR signal of the viral load (VL) assay and plasma drug determination (C24h). Patients and methods: An observational single-centre study enrolling patients with VL 50 ng/mL, the target effective concentration. Conclusions: In this clinical cohort of virologically-suppressed patients switching to a new STR, most subjects had adequate rilpivirine C24h and displayed a high level of virological suppression with no residual viremia until W96.

Date: 2015
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134430 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 34430&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0134430

DOI: 10.1371/journal.pone.0134430

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().